ArticleInfectious diseases of poverty2023
Epidemiology of pediatric schistosomiasis in hard-to-reach areas and populations: a scoping review.
Article in Infectious diseases of poverty, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Prevalence of schistosomiasis and its association with anemia in Ethiopia, 2024: a systematic review and meta‑analysis.BMC infectious diseases · 2024Pooled it
- Prevalence and correlations of schistosomiasis mansoni and schistosomiasis haematobium among humans and intermediate snail hosts: a systematic review and meta-analysis.Infectious diseases of poverty · 2024Pooled it
- Effects of paediatric schistosomiasis control programmes in sub-Saharan Africa: A systematic review.PloS one · 2024Pooled it
- Impact of climate change on the global circulation of chikungunya virus: current evidence, future projections, and adaptation strategies.Infectious diseases of poverty · 2026Review
- Incidence, trend and distribution of reported cases of schistosomiasis to health facilities in the Volta Region, Ghana, 2019-2023.BMC infectious diseases · 2026Article
- Schistosomiasis japonica transmission dynamics: mathematical modeling in guiding One Health approach control strategies.Infectious diseases of poverty · 2026Article
- Prevalence of schistosome infection among children under two years of age: a brief report from medium-to-high endemic regions of Schistosoma mansoni in Madagascar.Tropical medicine and health · 2025Article
- Prevalence and factors associated with urinary schistosomiasis in women attending cervical cancer screening in Sithobela, Eswatini: A facility-based cross-sectional study.Helminthologia · 2025Article
- Schistosomiasis treatment in young children: a welcome step towards deployment of the paediatric praziquantel formulation.International health · 2025Article
- Considerations and expectations for the administration of dispersible arpraziquantel to young children: a landscape analysis.International health · 2025Article
- Does schistosome infection affect behavior through the gut-brain axis?PLoS neglected tropical diseases · 2025Article
- Priority knowledge gaps for schistosomiasis research and development in the World Health Organization Africa Region.Infectious diseases of poverty · 2025Article
- Schistosomiasis and Intestinal Helminthiases in a Remote Area of Central Madagascar.Journal of tropical medicine · 2025Article
- Schistosomiasis transmission in Zimbabwe: Modelling based on machine learning.Infectious Disease Modelling · 2024Article
- Role of social innovations in health in the prevention and control of infectious diseases: a scoping review.Infectious diseases of poverty · 2024Article
- Development of an automated artificial intelligence-based system for urogenital schistosomiasis diagnosis using digital image analysis techniques and a robotized microscope.PLoS neglected tropical diseases · 2024Article
- Impact of climate change on the global circulation of West Nile virus and adaptation responses: a scoping review.Infectious diseases of poverty · 2024Article
- Contextual factors influencing schistosomiasis treatment and identification of delivery platforms for arpraziquantel in hard-to-reach areas and populations in Homa Bay County, Kenya.PLOS global public health · 2024Article
- IgG persistence showed weak clinical aspects in chronic schistosomiasis patients.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis affects over 250 million people worldwide. Despite children and the poor being key risk groups, limited research and control activities target pre-school aged children (PSAC) and hard-to-reach populations. As endemic countries shift the goals of their schistosomiasis programs from morbidity control to disease elimination, there is a need for inclusive planning to cover all affected age groups from all geographical areas and populations to achieve sustainable impact and health equity.
methodsWe conducted searches in MEDLINE, Web of Science, Embase (Ovid), and LILACS per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for Scoping Reviews (PRISMA-ScR) guidelines. Quality assessment of identified articles was done using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. Relevant study data were extracted from the articles and entered into Microsoft Excel 2016 for descriptive analysis.
resultsFrom the 17,179 screened articles, we identified 13 eligible studies on schistosomiasis in PSAC living in hard-to-reach areas and populations. All identified studies were from sub-Saharan Africa. The mean sample size of the retained studies was 572, with a balanced sex distribution among the young children sampled in each study. Ten studies investigated Schistosoma mansoni, one investigated Schistosoma haematobium, while two covered both S. mansoni and S. haematobium in the target population. The prevalence of S. mansoni among PSAC in the included studies was estimated at 12.9% in Ghana, 80.3-90.5% in Kenya, 35.0% in Madagascar, 9.6-78.0% in Senegal, 11.2-35.4% in Sierra Leone, 44.4-54.9% in Tanzania and 39.3-74.9% in Uganda. Out of the three studies that investigated S. haematobium, the presence of the infection was reported in only one study carried out in Nigeria. Schistosome infections reported in nearly all studies included in this review were of light intensity. Only one study conducted in Nigeria documented visible hematuria in 17.7% of the PSAC studied.
conclusionsThe findings document the high prevalence of schistosomiasis among PSAC in hard-to-reach populations and underscore the need to consider this population subgroup when designing the expansion of preventive chemotherapy and schistosomiasis control activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.